Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMUNINE exposure and inhibitor monitoring before transition to BAX 326 study 250901
2009-016719-39Phase 4Completed
- Sponsor
- Baxter International Inc.
- Start
- Feb 2010
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of coagulation factor ix in hemophilia B (HB), sponsored by Baxter International Inc. Primary endpoint: Exposure to IMMUNINE and factor IX inhibitor monitoring. Started Feb 2010; status: completed.
02
Drugs
coagulation factor ix
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on 2009-016719-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016719-39.